Latest Milestone Payments News

Norwood Systems Limited reported a significant revenue increase for the half-year ended December 2025, alongside a widening net loss and strategic progress with Tier-1 telecom customers. The company secured additional funding and advanced its AI-driven voice platforms in collaboration with global hyperscalers.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Aurora Energy Metals has completed the sale of its Aurora Uranium Project to Eagle Nuclear Energy, receiving A$24.2 million in equity and retaining future milestone-linked payments and royalties.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.

Conrad Asia Energy has triggered a US$5 million milestone payment from PT Nations Natuna Barat, marking a key step towards production at the Mako gas field targeted for late 2027. The company also resolved a cash call dispute with Empyrean, strengthening its financial footing.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

Norfolk Metals has confirmed the US$250,000 option payment for the Carmen Copper Project in Chile and completed the environmental impact report, setting the stage for further exploration and eventual ownership consolidation.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Tempest Minerals has completed the sale of its Yalgoo Project to Capricorn Metals for $4.5 million in cash and shares, while retaining key iron ore rights. The deal includes potential milestone payments tied to future gold discoveries and mining progress.